H.I.G. Capital News
Contact:Corporate Communications Contact:
Chris Erdman MacDougall Biomedical Communications 508.647.0209 x14
NeurAxon, Inc. to Make Multiple Presentations at the International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters
WALTHAM, MA - May 18, 2010 - NeurAxon, Inc. today announced several scientific presentations by officers and advisors to the Company at the International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters, May 27 - 28, 2010 in Toronto, Ontario. NeurAxon is focused on the discovery and development of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.
The following presentations related to the Company and its technology will take place on Thursday,
May 27, 2010 at the MaRS Center Auditorium in Toronto, Ontario:
- 11:15 a.m. Presentation by John Andrews, Ph.D., Chief Scientific Officer of NeurAxon, entitled “Nitric Oxide Modulation of Sensitisation of Multiple Transmitter Systems in CNS Disorders”
- 2:00 p.m. Presentation by Frank Porreca, Ph.D., Chairman of the NeurAxon Scientific Advisory Board, entitled “Preclinical Evidence Implicating NO in Migraine Pathophysiology”
- 3:00 p.m. Presentation by Shawn Maddaford, Ph.D., Vice President of Discovery Chemistry of NeurAxon, entitled “Crossing the Structural Barriers in the Rational Design of Single and Dual Action nNOS Inhibitors for the Treatment of Pain”
- 3:30 p.m. Presentation by Jes Olesen, M.D., member of the NeurAxon Scientific Advisory Board, entitled “NO and CO Involvement in Migraine Pathophysiology”
About NeurAxon, Inc.
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.